A publicly-traded biopharmaceutical company, which had just emerged out of bankruptcy protection, retained CRA to conduct its intangible asset and goodwill impairment testing. First, CRA performed a ASC 360 recoverability test of the company’s intangible asset group, which included distribution agreements, customer relationships, non-compete agreements, and trade name. CRA then conducted a ASC 350 goodwill impairment analysis, which included both a comparison of the company’s carrying value with its fair value as well as a hypothetical purchase price allocation, to determine the goodwill impairment loss.
Patent Damages: Recent Trends in Daubert Decisions
In this Insights, we update the Daubert Decision trends in last year’s Insights with 2021 data.[1] Daubert Decision trends are based on our review of available...